J&J Q2 Earnings

On Wednesday, Johnson & Johnson ($JNJ@US) stated that COVID-19 vaccine sales are expected to be about $2.5 billion in their second-quarter earnings report. This is despite worries about the vaccine's safety and efficacy against the highly contagious delta variant. Johnson & Johnson outperformed analysts on the whole, and its stock was up 0.94% at press time.